AI Transformers Match Patients to Cancer Treatments, Fixing 95% Failures
95% of cancer trials fail due to poor patient-tumor-treatment matching; Noetik's TARIO-2 autoregressive transformer predicts 19,000-gene spatial maps from standard H&E slides, enabling precise cohort selection and GSK's $50M licensing deal.
Cancer Trial Failures Stem from Poor Patient-Tumor Matching
Cancer comprises hundreds or thousands of unique diseases, each with distinct biology, leading to a 95% clinical trial failure rate despite $20-30B annual investment and hundreds of trials yearly. Many "failed" treatments actually work but on mismatched patients—those without the right tumor biology. Better matching via biomarkers improves success dramatically, potentially saving millions of lives using existing safe drugs that stalled in trials. Translation from lab (e.g., mouse models, cell lines) to clinic fails because standard care lacks rich tumor profiling; ~0% of patients get whole-plex spatial transcriptomics, the richest readout.
Noetik's Multimodal Data Pipeline Creates "Virtual Cells"
Noetik spent two years collecting thousands of real human tumors, generating hundreds of millions of images across four modalities: spatial transcriptomics (1000+ channels), spatial proteomics, H&E imaging, and whole exome sequencing. This data trains massive self-supervised models forming "virtual cells" with deep cancer biology understanding, distinguishing tumor types (even novel ones) and simulating patient responses to treatments. Scaling laws show no limits, outperforming synthetic data sources.
TARIO-2 Predicts Rich Tumor Maps from Routine H&E Slides
TARIO-2, an autoregressive transformer trained on the world's largest tumor spatial transcriptomics datasets, predicts ~19,000-gene spatial maps directly from H&E assays every patient already receives. This unlocks precise cohort selection for trials, reviving safe-but-ineffective drugs by identifying responsive subgroups. Unlike discovery-focused AI (often turning tools into drug companies), Noetik licenses platforms; GSK's $50M deal plus undisclosed long-term commitments validates this, signaling pharma's appetite for AI software over single drugs.
Why This Beats Hype: Platform Licensing Over Drug Discovery
Big Pharma shifts from in-house AI development to licensing (e.g., Boltz, Isomorphic) because cohort selection addresses the core lab-to-clinic bottleneck. Noetik's approach guides discovery toward trial-successful drugs while matching existing ones, offering billions in savings and faster approvals without new molecules.